These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 23701329)

  • 1. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.
    Velkov T; Roberts KD; Nation RL; Thompson PE; Li J
    Future Microbiol; 2013 Jun; 8(6):711-24. PubMed ID: 23701329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.
    Velkov T; Roberts KD; Nation RL; Wang J; Thompson PE; Li J
    ACS Chem Biol; 2014 May; 9(5):1172-7. PubMed ID: 24601489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. History, Chemistry and Antibacterial Spectrum.
    Velkov T; Thompson PE; Azad MAK; Roberts KD; Bergen PJ
    Adv Exp Med Biol; 2019; 1145():15-36. PubMed ID: 31364069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?
    Bergen PJ; Landersdorfer CB; Zhang J; Zhao M; Lee HJ; Nation RL; Li J
    Diagn Microbiol Infect Dis; 2012 Nov; 74(3):213-23. PubMed ID: 22959816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug-Resistant Gram-Negative Pathogens: The Urgent Need for 'Old' Polymyxins.
    Paterson DL; Bonomo RA
    Adv Exp Med Biol; 2019; 1145():9-13. PubMed ID: 31364068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug-resistant Gram-negative infections: what are the treatment options?
    Giamarellou H; Poulakou G
    Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
    Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
    Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rediscovering the octapeptins.
    Velkov T; Roberts KD; Li J
    Nat Prod Rep; 2017 Mar; 34(3):295-309. PubMed ID: 28180225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Novel Polymyxin-Like Antibiotics.
    Velkov T; Roberts KD
    Adv Exp Med Biol; 2019; 1145():343-362. PubMed ID: 31364086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reviving Polymyxins: Achievements, Lessons and the Road Ahead.
    Li J
    Adv Exp Med Biol; 2019; 1145():1-8. PubMed ID: 31364067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymyxins: a new hope in combating Gram-negative superbugs?
    Velkov T; Roberts KD; Thompson PE; Li J
    Future Med Chem; 2016 Jun; 8(10):1017-25. PubMed ID: 27328129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymyxins for CNS infections: Pharmacology and neurotoxicity.
    Velkov T; Dai C; Ciccotosto GD; Cappai R; Hoyer D; Li J
    Pharmacol Ther; 2018 Jan; 181():85-90. PubMed ID: 28750947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of infections caused by Gram-negative pathogens: current status on the pharmacokinetics/pharmacodynamics of parenteral and inhaled polymyxins in patients.
    Lin YW; Aye SM; Rao G; Zhou QT; Chan HK; Li J
    Int J Antimicrob Agents; 2020 Dec; 56(6):106199. PubMed ID: 33075510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rescuing the Last-Line Polymyxins: Achievements and Challenges.
    Nang SC; Azad MAK; Velkov T; Zhou QT; Li J
    Pharmacol Rev; 2021 Apr; 73(2):679-728. PubMed ID: 33627412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colistin, mechanisms and prevalence of resistance.
    Bialvaei AZ; Samadi Kafil H
    Curr Med Res Opin; 2015 Apr; 31(4):707-21. PubMed ID: 25697677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
    Zavascki AP; Goldani LZ; Li J; Nation RL
    J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?
    Blaskovich MAT; Pitt ME; Elliott AG; Cooper MA
    Expert Rev Anti Infect Ther; 2018 Jun; 16(6):485-499. PubMed ID: 29848132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure--activity relationships of polymyxin antibiotics.
    Velkov T; Thompson PE; Nation RL; Li J
    J Med Chem; 2010 Mar; 53(5):1898-916. PubMed ID: 19874036
    [No Abstract]   [Full Text] [Related]  

  • 19. A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens.
    Roberts KD; Zhu Y; Azad MAK; Han ML; Wang J; Wang L; Yu HH; Horne AS; Pinson JA; Rudd D; Voelcker NH; Patil NA; Zhao J; Jiang X; Lu J; Chen K; Lomovskaya O; Hecker SJ; Thompson PE; Nation RL; Dudley MN; Griffith DC; Velkov T; Li J
    Nat Commun; 2022 Mar; 13(1):1625. PubMed ID: 35338128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes.
    Almangour TA; Garcia E; Zhou Q; Forrest A; Kaye KS; Li J; Velkov T; Rao GG
    Int J Antimicrob Agents; 2021 Jun; 57(6):106328. PubMed ID: 33785362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.